SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
George D. Demetri(Dana-Farber Cancer Institute), Michael C. Heinrich(VA Portland Health Care System), Charles M. Baum(Brigham and Women's Hospital), A. Kazanovicz(Brigham and Women's Hospital), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Jayesh Desai(Peter MacCallum Cancer Centre), A. Van Den Abbeele(Brigham and Women's Hospital), Jeffrey A. Morgan(Sheba Medical Center), Jonathan A. Fletcher(Harvard University), Christopher D.�M. Fletcher(Brigham and Women's Hospital)
Cited by 103
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k